brain-cancer

Key regulatory axis keeps brain cancer stem cells alive and fuels drug resistance in childhood brain tumors

Sonic Hedgehog medulloblastoma (SHH-MB) is a brain tumor that can relapse after treatment, driven by stem/progenitor-like cells that resist chemotherapy. Understanding what maintains these cells is critical to preventing relapse. This study identified a molecular axis — REST → AKT → SOX2 — that preserves the stem cell compartment in SHH-MB.

REST (a transcriptional repressor) was found to activate AKT signaling, which in turn stabilizes SOX2 protein, a master regulator of stemness. The result is a regulatory loop that sustains cancer stem cells. Additionally, these cells use Midkine (a signaling molecule) to communicate with neighboring cells, potentially spreading stem-like properties or creating a permissive niche.

Targeting the REST-AKT-SOX2 axis — or blocking Midkine signaling — could represent new strategies to eliminate the chemoresistant stem cell population in SHH-MB.

Key Findings

REST transcription factor preserves the stem/progenitor compartment in SHH medulloblastoma
REST activates AKT signaling, which enhances SOX2 protein stability
REST-AKT-SOX2 axis is identified as a driver of stemness and chemoresistance
Midkine-mediated intercellular communication is regulated by this axis
Targeting this pathway could eliminate chemotherapy-resistant stem cells

Implications

Medulloblastoma relapse is frequently fatal in children. If REST-AKT-SOX2 inhibition can selectively target the stem cell population, it could reduce relapse rates. AKT inhibitors already exist in the clinic, which could accelerate translation. Midkine as a therapeutic target also has clinical-stage inhibitors in development.

Caveats

Preprint — not peer reviewed. Based on abstract only. Mechanistic data likely from cell lines or mouse models — human tumor validation details not available from abstract. SHH-MB is a specific medulloblastoma subtype; findings may not generalize. AKT inhibition has broad effects that could limit tolerability in pediatric patients.

Source: bioRxiv — 2026-04-09

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.